Michael R. Page, PharmD, RPh

Articles

Repatha Offers Additional LDL-C Reduction in a Convenient Dosage Form

March 30, 2017

Richard Mullvain, RPh, BCPS (AQC), CCCC, a cardiovascular clinical pharmacist and expert in cardiovascular care at the Essentia Health Heart & Vascular Center in Duluth, Minnesota, delivered a focused clinical review on the topic of the PCSK9 inhibitor Repatha (evolocumab), and its impact on low-density lipoprotein cholesterol (LDL-C).